Petrus Trust Company’s NovoCure NVCR Stock Holding History

Petrus Trust Company’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-3,415	Closed	-$288K	–	284
2019 Q4	$288K	Buy	+3,415	New	+$276K	0.05%	137

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCP

Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Petrus Trust Company's NVCR Position: Q1 2020 in Review

Petrus Trust Company sold out of NovoCure (NVCR) in Q1 2020, closing a stake of 3,415 shares — an estimated $288K sold.

Petrus Trust Company first reported a position in NVCR in Q4 2019 and held it in 1 quarter. The position peaked at $288K in Q4 2019. 271 funds tracked by Wall St. Rank hold NVCR as of Q1 2020.

Petrus Trust Company reported no remaining NovoCure position as of Q1 2020 after selling out during the quarter.
Petrus Trust Company sold 3,415 NovoCure shares in Q1 2020, an estimated $288K.
Petrus Trust Company first reported a position in NovoCure in Q4 2019 and held it in 1 quarter.
Petrus Trust Company's NovoCure position peaked at $288K in Q4 2019.
271 funds tracked by Wall St. Rank held NovoCure as of Q1 2020.

Based on Petrus Trust Company's 13F filing for Q1 2020, filed 15 May 2020.